Polycystic ovary syndrome.
Conditions
Interventions
Intervention 1: Intervention group: this group consists of 48 women of reproductive age diagnosed with polycystic ovary syndrome. participants in this group will consume three capsules daily, each con
Sponsors
Gonabad University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Age between 18-45 years old Confirmation of Polycystic Ovary Syndrome (PCOS) based on meeting at least two out of the three Rotterdam criteria Presence of polycystic ovaries confirmed via ultrasonography according to the Amsterdam criteria. Presence of clinical hirsutism defined by a modified Ferriman-Gallwey score of 8 or higher A minimum of two years must have passed since the onset of menarche A BMI within the range of 18.5 to 30 kg/m² Presence of clinical or biochemical signs of hyperandrogenism, with the exclusion of other related etiologies (e.g., non-classical congenital adrenal hyperplasia, Cushing’s syndrome) based on clinical history and self-reports. No prior history of oophorectomy or any surgical intervention on one or both ovaries Absence of underlying systemic or psychiatric disorders according to clinical history and participant self-disclosure. Non-smoker and no history of substance abuse based on self-reported data No known hypersensitivity or allergic reaction to Sumac (*Rhus coriaria*) No consumption of antioxidant supplements (e.g., Vitamins E and C) prior to or during the study period Not undergoing any specialized dietary or therapeutic regimens before or during the trial No history of major stressful life events within the past three months based on self-reported information
Exclusion criteria
Exclusion criteria: Being a smoker History of oophorectomy or any surgical intervention on one or both ovaries Consumption of antioxidant supplements (e.g., Vitamins E and C) prior to or during the study period Hypersensitivity or allergic reaction to Sumac
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Follicle-Stimulating Hormone. Timepoint: At study onset and 12 weeks after the initiation of the intervention. Method of measurement: ELISA.;Luteinizing Hormone. Timepoint: At study onset and 12 weeks after the initiation of the intervention. Method of measurement: ELISA.;Size of dominant ovarian follicle. Timepoint: At study onset and 12 weeks after the initiation of the intervention. Method of measurement: Ultrasound. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahareh khajehpour
Gonabad University of Medical Sciences
Outcome results
None listed